Publié le 07 mars 2014


Antony (France), 5 March 2014 – During its meeting held on March 5, 2014, the Board of Directors of Stallergenes announced the appointment of Christian CHAVY as Chief Executive Officer, to replace Roberto GRADNIK. This appointment will be effective on March 31, 2014.

The appointment of Christian CHAVY will enable the Group to pursue its strategy and to support Stallergenes in promising markets for immunotherapy, with a particular focus on the US market.

Roberto GRADNIK will ensure a smooth transition and will provide consultancy services to the Board of Directors during a four-month transitional period.

Patrick LANGLOIS, Chairman of the Board of Directors, commented:

“On behalf of the Board of Directors, I would like to warmly thank Roberto GRADNIK, who has successfully implemented a new organization adapted to the new operational challenges faced by the Group. Under his leadership, the Group made a major breakthrough, with the preparation and submission of the application for commercial authorisation of Oralair®tablets in the US, which is currently reviewed by the FDA, and the definition of a long-term strategy, with a particularly strong focus on international markets. The appointment of Christian CHAVY represents a continuation of this strategy. His recognised management skills, his international experience and considerable knowledge of the pharmaceuticals industry will enable Stallergenes to continue its expansion into promising markets for immunotherapy and in particular to ensure the success of Oralair® in the US market.”

In 2010, Christian CHAVY joined ARES Life Science, an investment fund dedicated to healthcare. Previously, he served as President of Global Operations for Actelion Pharmaceuticals (USA, Europe, Japan and rest of the world). Prior to joining Actelion, he was Vice President at the reproductive medicine strategic unit of Serono in Geneva and Chairman of Serono’s French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France. Christian CHAVY is a graduate of ESSEC and Institut de Contrôle de Gestion de Paris (ICG).


STALLERGENES is a global healthcare company specialized in the diagnosis and treatment of allergies. For more than 50 years, it has been continuously expanding the existing frontiers of science in order to provide allergy patients with more effective long lasting therapeutic options. Thanks to its innovation strategy, fueled by investments amounting to around 20% of total annual revenues as well as external cooperations, STALLERGENES is able to provide targeted allergen immunotherapy-based allergy solutions that significantly improve the lives of allergy patients around the world.

STALLERGENES operates in 20 countries and employs over 1,000 people. In 2013, the Company generated total revenues of € 248 million, and more than 500,000 patients were treated with STALLERGENES products.

For more information please visit the company website at:

Euronext Paris (Compartment B)
CAC small
ISIN: FR0000065674
Reuters: GEN.PA
Bloomberg: GEN.FP

Forward-looking statements related to Stallergenes

This press release may contain forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes’ management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.


Investor and analyst relations
Peter Buhler
Chief Financial Officer
Phone: +33 1 55 59 20 95

Investor and press relations agency
FTI Consulting – Analyst and investor contact
Stephan Dubosq
Phone: +33 1 47 03 68 16

Media Relations
Lise Lemonnier
Senior Communication & Public Affairs Director
Phone: + 33 1 55 59 20 96

FTI Consulting – Press contact
Jeanne Bariller
Phone: +33 1 47 03 68 63